Baxdrostat by AstraZeneca shows significant blood pressure reduction in Phase III trial, advancing treatment for resistant hypertension. Promising results showcase its safety and effectiveness.
AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.
Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
Discover AstraZeneca's Enhertu's promising trial results for HER2-positive early breast cancer, showcasing significant survival improvements and plans for regulatory approval.
Discover AstraZeneca's strategic shift in its listing structure, enhancing global investor access and compliance with UK governance. Key insights from the September 2025 Form 6-K.
Explore AstraZeneca's SEC Form 6-K insights on revenue growth, U.S. market strategies, and a proposed NYSE listing. Strong buy recommendation for investors eyeing future gains.
Explore AstraZeneca PLC's latest 6-K report detailing a transaction by Non-Executive Director Karen Knudsen involving 9 ADSs. Key insights for September 2025 compliance.
AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.
AstraZeneca's report highlights Tezspire's EU approval for CRSwNP, showcasing significant trial results and market potential. A game-changer for 320M affected globally.
Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.
AstraZeneca's 6-K filing reveals the RESOLUTE Phase III trial results for Fasenra in COPD. The treatment showed numerical improvements but did not meet primary endpoint significance.
Discover AstraZeneca PLC's latest Form 6-K detailing voting rights and share capital as of August 31, 2025. Key info for shareholders on compliance and transparency.